antibody

Human RASSF1A antibody

ARF0501

50 ul

170 USD

monoclonal

mouse

nonconjugated

3F3

western blot, ELISA, immunocytochemistry

Human RASSF1A antibody

ARF0501

NP_009113

The tumor suppressor gene RASSF1A (3p21.3), human Ras association domain family 1A, is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, small intestine, colon, and peripheral blood leukocytes. RASSF1A expression is inhibited by hypermethylation of the CpG island including the promoter and early transcribed regions of the human RASSF1A gene. Hypermethylated RASSF1A promoter is observed in primary tumors. Furthermore, RASSF1A is related with cell cycle regulation, apoptosis and microtubule stability.

RASSF1(Ras association (RalGDS/AF-6) domain family 1),123F2, RDA32, NORE2A, RASSF1A, REH3P21, Ras association (RalGDS/AF-6) domain family member 1

1mg/ml (determined by BCA assay)

Liquid in. Phosphate-Buffered Saline (pH 7.4) with 0.02% Sodium Azide, 10% glycerol

Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.

Agathanggelou A, et al., (2005) Cancer Res. 65, 3497-3508.;; Lerman MI. et. al. (2000) Cancer Res. 60, 6116-6133.;; Strunnikova M. et al., (2005) Mol Cell Biol. 25, 3923-3933.;; Dammann R. et al., (2005) Histol Histopathol. 20, 645-663.;; Rossa W.k, et al., (2007) American Journal of pathology. 170, 941-950.

Mouse

IgG1 kappa

Recombinant human RASSF1A (1-340aa) purified from E. coli.

ELISA, WB, ICC/IF

ICC/IF analysis of RASSF1A in HeLa cells. The cell was stained with ARF0501 (1:100). The secondary antibody (green) was used Alexa Fluor 488. DAPI was stained the cell nucleus (blue).ICC/IF analysis of RASSF1A in A431 cells. The cell was stained with ARF0501 (1:100). The secondary antibody (green) was used Alexa Fluor 488. DAPI was stained the cell nucleus (blue).{ARF0501-IF2.jpg}

Cell lysate (40ug) was resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human RASSF1A (1:500). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.;;Lane 1.: HeLa cell lysateCell lysates (5ug) were resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human RASSF1A (1:1000). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.;;Lane 1.: 293T cell lysate;;Lane 2.: RASSF1A transfected 293T cell lysate{2004010525238693.jpg}

Human

3F3

The antibody has been tested by ELISA, Western blot and ICC/IF analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results.

Human

Cancer

Unconjugated

Monoclonal

By protein-A affinity chromatography

Monoclonal Antibody

Q9NS23

RASSF1A,ARF0501-10ug,ARF0501-20ug,ARF0501-50ug,ARF0501-100ug,ARF0501-250ug,ARF0501-500ug,ARF0501-1mg,ARF0501-10,ARF0501-20,ARF0501-50,ARF0501-100,ARF0501-250,ARF0501-500,ARF0501-1

Thaler S, et al. RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development. (Oncogene. 2012){https://pubmed.ncbi.nlm.nih.gov/22266866/};;Dratviman-Storobinsky O, et al. The role of RASSF1A in uveal melanoma. (Invest Ophthalmol Vis Sci. 2012){https://pubmed.ncbi.nlm.nih.gov/22447862/};;Gou HF, et al. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. (PLoS One. 2013){https://pubmed.ncbi.nlm.nih.gov/23637996/};;Korah R, et al. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma. (Mol Cancer. 2013){https://pubmed.ncbi.nlm.nih.gov/23915220/};;Beckedorff FC, et al. The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. (PLoS Genet. 2013){https://pubmed.ncbi.nlm.nih.gov/23990798/};;Ram RR, et al. RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression. (Mol Cell Biol. 2014){https://pubmed.ncbi.nlm.nih.gov/24732797/};;Pruikkonen S, Kallio MJ. Excess of a Rassf1-targeting microRNA, miR-193a-3p, perturbs cell division fidelity. (Br J Cancer. 2017){https://pubmed.ncbi.nlm.nih.gov/28449010/};;Li W, et al. Suppressor of hepatocellular carcinoma RASSF1A activates autophagy initiation and maturation. (Cell Death Differ. 2019){https://pubmed.ncbi.nlm.nih.gov/30315205/};;Guo M, et al. RASSF1-AS1, an antisense lncRNA of RASSF1A, inhibits the translation of RASSF1A to exacerbate cardiac fibrosis in mice. (Cell Biol Int. 2019){https://pubmed.ncbi.nlm.nih.gov/30571844/};;Dabral S, et al. A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension. (Nat Commun. 2019){https://pubmed.ncbi.nlm.nih.gov/31086178/};;Francisco J, et al. The tumor suppressor RASSF1A modulates inflammation and injury in the reperfused murine myocardium. (J Biol Chem. 2019){https://pubmed.ncbi.nlm.nih.gov/31311858/};;Chen J, et al. 5-Aza-CdR Regulates RASSF1A By Inhibiting DNMT1 To Affect Colon Cancer Cell Proliferation, Migration And Apoptosis. (Cancer Manag Res. 2019){https://pubmed.ncbi.nlm.nih.gov/31807076/};;Slemmons KK, et al. Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma. (Cancer Res. 2020){https://pubmed.ncbi.nlm.nih.gov/32354737/};;Dhanaraman T, et al. RASSF effectors couple diverse RAS subfamily GTPases to the Hippo pathway. (Sci Signal. 2020){https://pubmed.ncbi.nlm.nih.gov/33051258/};;Jeon HJ, Oh JS. RASSF1A Regulates Spindle Organization by Modulating Tubulin Acetylation via SIRT2 and HDAC6 in Mouse Oocytes. (Front Cell Dev Biol. 2020){https://pubmed.ncbi.nlm.nih.gov/33195286/};;Jia J, et al. RAS-association domain family 1A regulates the abnormal cell proliferation in psoriasis via inhibition of Yes-associated protein. (J Cell Mol Med. 2021){https://pubmed.ncbi.nlm.nih.gov/33960627/};;Roßwag S, et al. RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2. (Cells. 2021){https://pubmed.ncbi.nlm.nih.gov/34831091/}